## ADUS: Addus HomeCare Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.08 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($107.32)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-13 | BMO Capital | $120 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-13 | BMO Capital | init | Market Perform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 1 ($0.00M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 54.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Blackrock Inc.: 14.8% (-1.1%)
- Vanguard Group Inc: 7.0% (+2.9%)
- Capital Research Glo: 6.5% (+9.0%)
- Wasatch Advisors LP: 5.1% (+0.8%)
- Silvercrest Asset Ma: 4.6% (+14.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.08 suggests fair value with growth premium. Balance sheet: low leverage (D/E 0.36). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.1B |
| Beta | 0.94 |
| 52W Range | $88.96 - $136.72 |
| Short Interest | 4.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.08 |
| Forward P/E | 16.7 |
| Current P/E | 18.5 |
| YoY Growth | 11.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -3.1% to -2.0% (+1.2% in 5 days), confirming momentum buildup. Below STRENGTH zone by 6.0pp (needs >4.0% for momentum thesis). MRS_5 turning positive (1.0%) - potential reversal signal. RSI neutral at 48.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.96% (CS: 31) | Neutral |
| RSI_14 | 48.5 | Neutral |
| MACD Histogram | -0.24 | Bearish |
| vs SMA20 | 1.002x | Above |
| vs SMA50 | 0.989x | Below |
| vs SMA200 | 1.042x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $114.36
- **Stop Loss:** $107.32 (6.2% risk)
- **Target:** $128.44 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 196
- **Position Value:** $22,414.56
- **Portfolio %:** 22.41%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-23 (Est: $1.72)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.53 | $1.56 | +1.7% |
| 2025Q2 | $1.46 | $1.49 | +1.8% |
| 2025Q1 | $1.33 | $1.42 | +6.5% |
| 2024Q4 | $1.36 | $1.38 | +1.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*